Breaking News

Financial Report: Amgen

April 23, 2014

Revenues up 7% in the quarter


1Q Revenues: $4.5 billion (+7%)

1Q Earnings: $1.1 billion (-25%)

Comments: Growth in the quarter was driven by newly launched Kyprolis, XGEVA (+25%), Prolia (+38%), and Neulasta sales (+5%). Enbrel sales were down 5% to $924 million and Aranesp sales were down 2% to $177 million, mainly due to lower demand. EPOGEN sales increased 6% to $462 million. Sensipar/Mimpara sales increased 2% to $178 million. Combined sales of Vectibix and Nplate increased 18% to $101 million. R&D expenses were up 17% to $994 million, attributed to the addition of Onyx programs. Earnings were impacted by the end of the ENBREL profit share in 4Q13.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision